#United States #Washington D.C. #Novo Nordisk #Wegovy #AASLD

Novo Nordisk to Present Key Wegovy® Data at AASLD 2025

Novo Nordisk has recently announced its participation in the upcoming 76th Annual American Association for the Study of Liver Diseases (AASLD) congress, known as The Liver Meeting® 2025, scheduled from November 7 to 11 in Washington D.C., United States. During this significant event, the company intends to showcase a total of 11 abstracts focusing on the clinical applications and implications of Wegovy® (semaglutide 2.4 mg), particularly in relation to metabolic dysfunction-associated steatohepatitis (MASH).

Key Highlights

Among the highlights of Novo Nordisk's presentations are clinical data and real-world findings that illustrate the effectiveness of Wegovy® in treating MASH and its relationship with weight loss across various patient demographics. The discussions will include essential findings from post-hoc analyses derived from the ESSENCE trial, which examines the specific impacts of Wegovy® in different stages of MASH disease progression.

Martin Holst Lange, the Chief Scientific Officer and Executive Vice President of Research and Development at Novo Nordisk, emphasizes the significance of this research, stating, "The breadth and depth of our clinical trial program reflect our commitment to enhancing health outcomes for patients grappling with serious chronic diseases like MASH."

Presentation Overview

The collection of data being presented encompasses critical insights into various dimensions of MASH. The accepted abstracts will cover topics such as:

• - Prevalence Studies: Evaluating the occurrence of steatosis and liver fibrosis in patients with MASH from non-hepatology centers across the U.S. and Europe.
• - Prognostic Analysis: Assessing MASH disease components that may indicate risk levels for secondary cardiovascular diseases as part of a post-hoc analysis.
• - Treatment Investigations: A phase 2 study focusing on the safety and efficacy of combined treatment methods including semaglutide for patients with compensated cirrhosis stemming from MASH.
• - Real-World Clinical Outcomes: Understanding the economic and health-related impacts based on fibrosis stages within the MASH population.

Understanding MASH and the Role of Semaglutide

Metabolic dysfunction-associated steatohepatitis (MASH) is a serious, progressive liver condition closely linked to obesity, often remaining asymptomatic in its early stages. As many as one in three individuals with overweight or obesity may be affected by this condition. An alarming statistic indicates that over 40% of those with MASH also have type 2 diabetes, underscoring the need for effective treatment strategies.

Semaglutide 2.4 mg is a glucagon-like peptide-1 receptor agonist that has received FDA’s accelerated approval to treat adults suffering from MASH with moderate to advanced liver scarring, but not those who have progressed to cirrhosis. The ongoing ESSENCE phase 3 trial aims to further evaluate the treatment benefits of semaglutide in this complex patient group.

Novo Nordisk's Commitment to Healthcare

Founded in 1923 and headquartered in Denmark, Novo Nordisk has established itself as a leader in the global healthcare sector. The company actively works to innovate and broaden access to its therapeutic solutions, aiming to combat serious chronic diseases.

Through its robust clinical research and presentations, Novo Nordisk continues to pioneer advancements in the understanding and management of liver diseases associated with metabolic dysfunction, as evidenced by its focus during the AASLD 2025 meeting.

This year's event promises to be a cornerstone of discussion around liver health and chronic disease management as healthcare professionals and researchers unite to share knowledge and strategies for better patient outcomes.